Personalis, Inc. (PSNL)
NASDAQ: PSNL · IEX Real-Time Price · USD
1.200
+0.005 (0.42%)
At close: Jul 2, 2024, 4:00 PM
1.230
+0.030 (2.50%)
After-hours: Jul 2, 2024, 7:00 PM EDT
Personalis Revenue
Personalis had revenue of $74.15M in the twelve months ending March 31, 2024, with 7.96% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $19.53M with 3.53% year-over-year growth. In the year 2023, Personalis had annual revenue of $73.48M with 12.97% growth.
Revenue (ttm)
$74.15M
Revenue Growth
+7.96%
P/S Ratio
0.84
Revenue / Employee
$332,493
Employees
223
Market Cap
62.33M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
Dec 31, 2019 | 65.21M | 27.43M | 72.62% |
Dec 31, 2018 | 37.77M | 28.38M | 302.15% |
Dec 31, 2017 | 9.39M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MDxHealth | 75.33M |
Burning Rock Biotech | 72.30M |
Theratechnologies | 57.85M |
Allurion Technologies | 48.78M |
Gritstone bio | 15.65M |
Adlai Nortye | 5.00M |
PSNL News
- 14 days ago - Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference - Business Wire
- 19 days ago - Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call - Business Wire
- 4 weeks ago - ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring - Business Wire
- 4 weeks ago - Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus - Business Wire
- 5 weeks ago - Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 - Business Wire
- 5 weeks ago - Antares Bolsters Private Wealth Team with Three New Senior Appointments - Business Wire
- 6 weeks ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Personalis Reports First Quarter 2024 Financial Results - Business Wire